Skip to main content
. Author manuscript; available in PMC: 2014 Mar 26.
Published in final edited form as: Nat Med. 2014 Jan 12;20(2):143–151. doi: 10.1038/nm.3443

Figure 5.

Figure 5

Selectively enhancing huFc-huFcγR interactions augments bNAb-mediated protection from viral infection in vivo. (a) Percentage weight change compared to day 0 and survival over time in FcγR-humanized mice treated with the indicated doses of wild-type huIgG1 6F12 bNAb or PBS before infection with PR8 virus. Weight change values represent mean ± s.e.m. n ≥ 4 mice per group. (b) Percentage weight change compared to day 0 and survival over time in FcγR-humanized mice treated with wild-type huIgG1 6F12 bNAb, GASD/ALIE mutant 6F12 bNAb or PBS before infection with PR8 virus. Weight change values represent mean ± s.e.m. n ≥ 12 mice per group. Significant differences between wild-type IgG1 mAb–treated and GASD/ALIE mAb–treated groups are shown: **P < 0.01.